Chien, Wei-Chen
Tsai, Tsen-Fang http://orcid.org/0000-0002-1498-1474
Article History
Accepted: 30 November 2023
First Online: 30 December 2023
Declarations
:
: The authors received no funding for the preparation of this article.
: Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen-Cilag, Merck Sharp & Dohme, Novartis International AG, Pfizer, Inc, and UCB Pharma. Wei-Chen Chien has no conflicts of interest that are directly relevant to the content of this article.
: Not applicable. This study is a narrative review of previously published peer-reviewed literature and does not involve any use of human or animal data. Therefore, ethics approval is not required.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Conceptualization: T-FT; methodology: W-CC, T-FT; writing, original draft preparation: W-CC; writing, review and editing: T-Fs; supervision: T-FT. All authors have read and approved the final version of the manuscript.